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for diabetes mellitus following renal transplantation
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Autosomal-dominant polycystic kidney disease as a risk factor
for diabetes mellitus following renal transplantation.
Background.Posttransplant diabetes mellitus is an important
complication of renal transplantation that is associated with a
significant impact on quality of life and an increase in long-term
morbidity and mortality. Autosomal-dominant polycystic kid-
ney disease (ADPKD) is a hereditary disease that commonly
leads to end-stage renal disease (ESRD) in adulthood. The asso-
ciation between ADPKD and posttransplant diabetes mellitus
has not been previously studied in a large cohort of patients.
Methods. To address this question, we studied a cohort of 135
patients with ADPKD who received a first renal-only transplant
between January 1985 and December 1999. An age, race, and
date of transplant-matched cohort of 135 non-ADPKD subjects
were used as the control population.
Results. The cohorts were similar at baseline for gender dis-
tribution, body mass index (BMI), proportion of obese subjects
(BMI greater than 30 kg/m2), family history of diabetes melli-
tus, and type of donor (deceased or living). At 12 months, the
incidence of posttransplant diabetes mellitus was significantly
higher in patients with ADPKD when compared to the controls
(17% vs. 7.4%) (P = 0.016), despite no significant differences in
the BMI, percent increase in BMI, number of acute rejections,
prednisone dose at 3 and 6 months, use of diuretics or beta
blockers, delayed graft function, or serum creatinine levels. The
proportion of subjects requiring insulin was significantly higher
in the ADPKD group (11.1% vs. 3%) (P = 0.009).
Variables significantly associated with posttransplant dia-
betes mellitus at 1 year by bivariate analyses were the diagnosis
of ADPKD (P = 0.02), BMI at transplant (P = 0.04), obesity
at 12 months (P = 0.01), and delayed graft function (P = 0.02).
Gender of recipient (P = 0.9), family history of diabetes (P =
0.3), prednisone dose at 3 months (P = 0.9) and 6 months (P =
0.7), acute rejection (P = 0.9), use of beta blockers or tacrolimus
(P = 0.8), deceased donor transplant (P = 0.2), and serum crea-
tinine at 1 year (P = 0.5) were not associated with posttransplant
diabetes mellitus. A trend toward increased incidence of post-
transplant diabetes mellitus was found with the use of diuretics
post transplant (P = 0.054). By multivariable analyses, in pa-
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tients with ADPKD, the adjusted (by all the variables listed
above) relative risk for development of posttransplant diabetes
mellitus was 2.87 (95% CI = 1.24–6.65) (P = 0.014). Only the
diagnosis of ADPKD (RR = 2.9) (P = 0.01), obesity at 1 year
(RR 2.5) (P = 0.017), and delayed graft function (RR 2.4) (P =
0.03) contributed significantly to the fit of a stepwise logistic re-
gression model. Patient survival was significantly worse in the
cohort of patients who developed posttransplant diabetes mel-
litus (median survival 109.3 vs. 121 months) (P = 0.008).
Conclusion. In our study patients with ADPKD were at
a threefold increased risk for development of posttransplant
diabetes mellitus within the first year following renal transplan-
tation. Development of posttransplant diabetes mellitus was
associated with a significant detrimental impact on patient sur-
vival. Further studies are needed to provide insight into the
mechanisms of the association between ADPKD and posttrans-
plant diabetes mellitus.
End-stage renal disease (ESRD) is prevalent and a
costly condition. The number of Americans suffering
from ESRD was estimated to be more than 300,000 by the
end of 2000 with 85,500 new patients starting ESRD care
in 2000 [1]. During the same year, 63,000 patients with
ESRD died in the United States. The annual Medicare ex-
penditure for ESRD care was estimated to have exceeded
$12 billion in 1998 [1]. Renal transplantation is considered
to be the most cost-effective therapy for patients with
ESRD. Autosomal-dominant polycystic kidney disease
(ADPKD) is one of the most common genetic diseases
in humans. It affects all ethnic groups with a prevalence
ranging from 1 in 500 to 1 in 1000 live births [2]. Most fam-
ilies with ADPKD have defective genes on chromosome
16 (pkd1) or on chromosome 4 (pkd2) [3, 4]. These gene
mutations account for almost all the cases of ADPKD
identified so far. The proteins coded by these genes have
recently been identified and are categorized as members
of a new family, the polycystins. The product encoded by
pkd1 gene, polycystin-1, is an integral membrane protein
composed of 4302 amino acids with a large extracellu-
lar domain [5–7]. The exact function of polycystin 1 is
still under investigation; however, based on its molecu-
lar structure, it may function as a membrane receptor.
Polycystin 2, the molecule encoded by the pkd2 gene, is
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also a membrane-associated protein, but its structure re-
sembles that of an ion channel [7]. It has been proposed
that polycystin 1 and polycystin 2 interact in a common
pathway, which could explain the reason why mutations
of either the pkd1 or pkd2 gene produce identical renal
and extrarenal manifestations [8]. In ADPKD patients,
progression to ESRD typically occurs during middle age.
The likelihood of ADPKD patients requiring dialysis is
estimated to be less than 2% below the age of 40 years,
and 50% to 75% during the seventh and eighth decades of
life. Accelerated progression to ESRD is seen in African
Americans, males, and in patients with the pkd1 genotype.
Currently ADPKD accounts for approximately 17% of
patients with ESRD in the United States (61,000 to 66,000
patients). ADPKD patients were the recipients of 7.5%
of all Medicare-paid renal transplants performed in the
United States in 1998 (1002 out of 13,272) [1].
Although short-term graft survival following renal
transplantation has significantly improved over the past
decade the incidence of long-term complications remains
high. Posttransplant diabetes mellitus is one of the most
important complications of renal transplantation. The in-
cidence of posttransplant diabetes mellitus following re-
nal transplantation has been reported to be between 2.5%
and 30% [9]. A recent report described an increased risk
of kidney graft loss and patient death with the develop-
ment of posttransplant diabetes mellitus [10]. In addition,
patients with posttransplant diabetes mellitus are at risk
for all the long-term complications of diabetes such as
retinopathy, neuropathy, and cardiovascular events [11].
Although several factors have been associated with the
development of posttransplant diabetes mellitus, older
age at the time of transplantation and recipient’s ethnicity
(Hispanic and African-American) have been cited as the
most significant risk factors for the development of post-
transplant diabetes mellitus [9, 12, 13]. Obesity has long
been recognized as a risk factor for development of dia-
betes mellitus in the general population. Likewise, recip-
ient weight at the time of renal transplantation has been
shown in large cohorts to significantly increase the risk
for posttransplant diabetes mellitus [14]. In a small series,
body weight increase following transplantation reached
only marginal significance [15]. The presence of diabetes
mellitus, especially type 2, in a first-degree relative is con-
sidered a risk factor for the development of diabetes mel-
litus in the general population. The association between
posttransplant diabetes mellitus and a family history of
diabetes mellitus has also been described in the renal
transplant literature [16, 17]. Despite clear evidence that
the use of glucocorticoids is associated with insulin resis-
tance and diabetes mellitus, studies that have attempted
to establish an association between the dosage of steroids
and posttransplant diabetes mellitus have been inconclu-
sive [18]. Acute rejection episodes are commonly treated
with high doses of glucocorticoids; therefore, the num-
ber of acute rejection episodes may be associated with
posttransplant diabetes mellitus. The use of thiazide di-
uretics and/or beta-blockers for treatment of edema and
hypertension has been associated with the development
of glucose intolerance in the general population. One re-
port has suggested the same association in posttransplant
diabetes mellitus [19]. In addition, for reasons still poorly
understood, the incidence of posttransplant diabetes mel-
litus after renal transplantation appears to be increasing
since 1995 [14]. A single report from France has described
an association between ADPKD and posttransplant dia-
betes mellitus [20]. In this study, posttransplant diabetes
mellitus occurred in 34.6% of APKD patients compared
to 15.3% in the control group (P < 0.005). However, this
study involved only 26 patients and failed to account for
several potential confounders.
The objective of the present study was to investigate
the association between ADPKD and posttransplant di-
abetes mellitus in a large cohort of kidney transplant
recipients.
METHODS
To assess the association between ADPKD and post-
transplant diabetes mellitus, we conducted a single-center
historical cohort study. Subjects enrolled in the study in-
cluded all primary kidney-only recipients with a diagnosis
of ADPKD who were transplanted between January 1,
1985 and December 31, 1999. A cohort of non-ADPKD
primary kidney-only recipients transplanted during the
same period was selected as a control population. An
exclusion criterion was the presence of diabetes melli-
tus preceding transplantation. The outcome of interest
was the development of posttransplant diabetes mellitus,
here defined as the new onset (i.e., after the date of trans-
plantation) of persistent hyperglycemia (random blood
glucose levels higher than 200 mg/dL, on two consecu-
tive measurements at least one day apart) documented at
least 30 days from an acute rejection episode. The main
explanatory variable was the presence of ADPKD before
transplantation. To explore the presence of confounding
and effect-modification among the primary explanatory
variables and other exposures of interest, a multivari-
able analysis was performed by constructing a logistic
regression model in which the following variables were
included: body mass index (BMI), calculated by the for-
mula weight (kg)/height (m)2, obesity (BMI greater than
30 kg/m2) at the time of transplantation, history of dia-
betes mellitus in first-degree relatives, dose of prednisone
(mg) at 3 and 6 months, change in BMI, presence of acute
rejection, and the use of a diuretic and/or a beta blocker
within the first year following transplantation. To ad-
dress potential confounding from variables such as age at
transplantation, ethnicity, and transplantation era, each
patient in the ADPKD cohort was matched with other
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kidney-only recipient by same ethnicity, age (±5 years),
and closest date of transplantation.
Previously published data [10] have suggested that pa-
tients with glomerulonephritis would have a lower risk
for developing posttransplant diabetes mellitus. As sev-
eral patients in the matched cohort had a diagnosis of
glomerulonephritis, the issue of selection bias was ad-
dressed by performing an additional analysis of the in-
cidence of posttransplant diabetes mellitus using a third
non-matched cohort comprised by 162 adult recipients
without the diagnosis of glomerulonephritis who were
transplanted in our institution between January1991 and
May 1997.
Statistics
Differences in the proportions for nominal data were
analyzed using the chi-square test. Student t test and the
Mann-Whitney test were used for comparisons involving
continuous variables. Variables found to be significant
in the univariate analyses (P value equal or lower than
0.2) were included in the multivariable model. A bino-
mial logistic regression model was constructed in order
to estimate risks and their 95% CIs. The product limit
(Kaplan-Meier) method was used to analyze patient and
graft survivals. Comparison between survival curves was
accomplished by utilizing the log-rank test. All P values
reported were two-sided. For the purpose of this study,
P values lower than 0.05 were considered statistically sig-
nificant. The SPSS version 11.1 (SPSS Inc., Chicago, IL,
USA) statistical program was used in all the analyses.
RESULTS
During the period of January 1985 to December 1999,
1562 primary renal-only transplants were performed at
our institution. A subset of 156 recipients had ADPKD
as the primary cause of renal failure. By record review,
21 subjects were excluded from the study cohort since a
diagnosis of diabetes mellitus was present prior to trans-
plantation. This resulted in 135 eligible patients in the
ADPKD group. A group of 135 non-ADPKD recipients
(control group) were matched to the ADPKD subjects
according to the following criteria: closest date of trans-
plantation, age (±5 years), and ethnicity. Control subjects
were excluded if they had a diagnosis of diabetes mellitus
prior to transplantation.
The causes of ESRD in the matched cohort were:
chronic glomerulonephritis or unknown cause (N = 50),
IgA nephropathy (N = 19), focal sclerosing glomeru-
lonephritis (N = 11), hypertensive nephrosclerosis (N =
11), reflux nephropathy (N = 10), interstitial nephri-
tis (N = 10), membranous nephropathy (N = 5), We-
gener’s granulomatosis (N = 5), membranoproliferative
glomerulonephritis (N = 4), hereditary nephritis (N =
Table 1. Patient demographics at baseline by study group
Autosomal-dominant
polycystic
kidney disease Control P value
Patients at risk number 135 135
Age (mean ± SEM)a 50.2 ± 0.7 49.6 ± 0.7 0.5
Gender (females)b % 44.4 39.3 0.4
Deceased donorb % 76.3 69.6 0.2
Body mass index (mean ±
SEM)
26 ± 0.4 25.1 ± 0.4 0.1
Body mass index greater
than 30 kg/m2b%
16.3 12.7 0.4
Tacrolimus useb % 11.1 11.8 0.9
Family history of diabetesa % 29.6 28.6 0.9
Delayed graft functiona % 23.7 28.1 0.4
aStudent t test.
bChi-square test.
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Fig. 1. Posttransplant diabetes mellitus (PTDM) during the first
year posttransplant for autosomal-dominant polycystic kidney disease
(ADPKD) and control groups. ∗Chi-Square test (P = 0.016 for the
comparison of ADPKD and control groups).
3), lupus nephritis (N = 3), rapid progressive glomeru-
lonephritis (N = 2), drug-induced nephrotoxicity (N =
1), and medullary cystic disease (N = 1).
There were 128 Caucasians, two Hispanics, two Asians,
one African American, and two Pacific Islanders in each
cohort. The mean age was, as expected, not different be-
tween the cohorts. Table 1 shows the other demographic
characteristics at the time of transplantation. The cohorts
were similar in terms of gender distribution, type of organ
donor, BMI, proportion of obese subjects, family history
of diabetes, and the presence of delayed graft function.
At 12 months following transplantation (Fig. 1) the pro-
portion of individuals that developed posttransplant di-
abetes mellitus was significantly higher in the ADPKD
cohort (17%) when compared with the control group
(7.4%) (P = 0.016), as was the proportion of subjects
requiring insulin (11% versus 3%, P = 0.009, ADPKD
versus control, respectively). These differences occurred
despite the lack of significant differences in BMI, percent
increase of BMI, and prevalence of obesity at 12 months.
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Table 2. Overall results obtained at 12 months following
transplantation
Autosomal-dominant
polycystic
kidney disease Controls P-value
Posttransplant diabetes
mellitusa %
17 7.4 0.016
Proportion of patients
on insulina %
11.1 3 0.009
Body mass index (mean
± SEM)b
28.6 ± 0.5 28.2 ± 0.5 0.58
Percent increase of
body mass indexb
10.4 ± 1.1 12.7 ± 0.9 0.11
Body mass index
greater than 30
kg/m2b%
33.8 34.3 0.9
Prednisone dose at 3
months (median,
mg/day)c
12.5 15 0.004
Prednisone dose at 12
months (median,
mg/day)c
7.5 7.5 0.6
Beta blocker usea % 25.2 32.6 0.18
Diuretic usea % 34.8 26.7 0.15
Number of acute
rejections (mean ±
SEM)b
0.62 ± 0.8 0.57 ± 0.8 0.6
Recipients with acute
rejectiona %
39.3 37.8 0.8
Creatinine at 12 months
(mean ± SEM)b
1.43 ± 0.3 1.68 ± 0.1 0.019
aChi-square test.
bStudent t test.
cMann-Whitney test.
There were no significant differences in the proportion
of recipients using beta blockers or diuretics, in the num-
ber of acute rejections, or the proportion of recipients
that experienced at least one episode of acute rejection
(Table 2). The median prednisone dose at 3 months and
the mean serum creatinine level at 12 months were signif-
icantly higher in the control group. There was no signifi-
cant difference in the prednisone dose between the study
groups at 6 months.
In the univariate analyses the factors significantly asso-
ciated with the development of posttransplant diabetes
mellitus were (Table 3) the diagnosis of ADPKD (RR
2.57) (P = 0.02), BMI at transplantation (RR 1.08) (P =
0.04), obesity at 1 year (RR 2.65) (P = 0.01), and the
presence of delayed graft function (RR 2.38) (P = 0.02).
The use of diuretics nearly reached statistical significance
(RR 2.07) (P = 0.054). All other variables were not signif-
icantly associated with the development of posttransplant
diabetes mellitus in our population. We then performed a
multivariable analysis in which all variables with a P value
equal to or lower than 0.2 in the univariate analyses were
included in a binomial logistic regression model (Table 4,
reduced model). The adjusted risk for the development
of posttransplant diabetes mellitus remained significantly
higher for the ADPKD cohort (RR 2.83) (P = 0.014).
Table 3. Risk factors for posttransplant diabetes
mellitus—Univariate analyses
RR 95% CI P value
Autosomal-dominant polycystic
kidney disease
2.57 1.17–5.63 0.02
Body mass index at transplant 1.08 1.01–1.17 0.04
Obesity at transplant (body mass
index >30kg/m3)
2.12 0.88–5.11 0.09
Body mass index at 1 year 1.06 0.99–1.14 0.06
Obesity at 1 year 2.65 1.26–5.54 0.01
Percentage increase in body mass
index
0.72 0.03–17.5 0.8
Prednisone dose at 3 months 1.0 0.94–1.07 0.9
Prednisone dose at 6 month 1.02 0.89–1.18 0.7
Delayed graft function 2.38 1.12–5.06 0.02
Diuretic use 2.07 0.99–4.34 0.054
Family history of diabetes 1.46 0.68–3.14 0.3
Deceased donor 1.77 0.70–4.49 0.2
Acute rejection 1.04 0.50–2.20 0.9
Creatinine levels at 12 months 0.5 0.39–1.57 0.5
Tacrolimus use 1.29 0.37–4.51 0.7
Beta blocker use 0.91 0.40–2.06 0.8
Gender (female) 1.03 0.49–2.15 0.9
Table 4. Autosomal-dominant polycystic kidney disease adjusted risk
ratio (RR) for posttransplant diabetes mellitus
Adjusted RR 95% CI P value
Reduced modela 2.83 1.24–6.49 0.014
Complete modelb 2.87 1.24–6.65 0.014
aAdjusted by body mass index at transplant, body mass index >30 kg/m2 at 1
year, presence of delayed graft function, and use of diuretic.
bAdjusted by body mass index at transplant, body mass index > 30 kg/m2 at
1 year, presence of delayed graft function, prednisone dose at 3 and 12 months,
family history of diabetes mellitus, deceased donor, presence of acute rejection,
creatinine at 12 months, use of diuretic or beta blocker, and gender of recipient.
To further investigate the presence of confounding by
variables not statistically associated with the outcome
of interest, a model including all the variables was built
(Table 4, complete model). Once again, the cohort of re-
nal transplant recipients with a diagnosis of ADPKD had
almost a threefold increased risk for the development of
posttransplant diabetes mellitus (RR 2.87) (P = 0.014).
Because of the previously described association be-
tween the use of tacrolimus and posttransplant diabetes
mellitus, an analysis of two-way interactions was con-
ducted by creating three additional variables: cyclosporin
and ADPKD, tacrolimus and control, and tacrolimus and
ADPKD. These variables were entered in the complete
model as such. None of these variables were indepen-
dently associated with the development of posttransplant
diabetes mellitus.
The non matched cohort was composed by 162 re-
cipients with the following diagnoses: reflux or obstruc-
tive nephropathy (N = 52), hypertensive nephrosclerosis
(N = 41), analgesic nephropathy (N = 16), Alport disease
(N = 12), medullary cystic disease (N = 4), hemolytic-
uremic syndrome (N = 2), amyloidosis (N = 1), un-
known (N = 28), and other (N = 5). The incidence of
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Fig. 2. Patient survival according to posttransplant diabetes mellitus
(PTDM) within the first year following transplantation.
posttransplant diabetes mellitus for this cohort was 8%
(13 patients), which was not statistically different than
the incidence of posttransplant diabetes mellitus in the
matched cohort (P = 0.9), but still different than the
ADPKD cohort (P = 0.02).
In order to investigate the significance of posttrans-
plant diabetes mellitus on long-term allograft and patient
survivals we then performed a survival analysis using the
product limit (Kaplan-Meier) method. Graft survival was
not significantly different between the ADPKD and the
matched cohort (158 versus 129 months) (P = 0.07). We
could not find a difference in patient survival (178 ver-
sus >180 months) (P = 0.5), ADPKD versus controls,
respectively. However, patient survival was significantly
worse in the subset of patients that developed posttrans-
plant diabetes mellitus within the first year posttransplant
(median survival 109.3 months versus 121 months in the
no- posttransplant diabetes mellitus cohort) (P = 0.008)
(Fig. 2), regardless of ADPKD status.
DISCUSSION
Posttransplant diabetes mellitus is a costly and frequent
complication of renal transplantation. Its incidence seems
to be increasing in recent years [14] for reasons that are
not clearly understood. The identification of a subset of
the transplant recipients at higher risk for this compli-
cation is important, since early intervention could re-
sult in improvement in quality of life and a reduction in
posttransplant care costs. This communication describes
ADPKD as a condition that is associated with the de-
velopment of posttransplant diabetes mellitus following
renal transplantation.
Since ADPKD leads to ESRD during the later decades
of life, transplantation is offered to ADPKD subjects at a
much later time in life than for other conditions leading to
chronic renal failure. Posttransplant diabetes mellitus has
also been described as more often in middle aged and el-
derly renal transplant recipients. An association between
ADPKD and posttransplant diabetes mellitus may not
have been described earlier because of the lack of atten-
tion to the confounding effect of age at transplantation.
In this report we have addressed this issue by using an
age-matched criterion to select the study cohorts.
The use of glucocorticoids as immunosuppressive
agents can be traced back to the early stages of human
renal transplantation [21]. These agents are still consid-
ered to be a cornerstone in many immunosuppressive
protocols. Glucocorticoids, though, are associated with
glucose intolerance in other conditions besides transplan-
tation. The attempts to establish a dose-response curve
have so far been disappointing. In our report, despite hav-
ing a statistically significant difference in the prednisone
dose at 3 months posttransplant (12.5 mg versus 15 mg
per day), ADPKD versus controls, respectively, we think
that this finding lacks clinical relevance. However, even
if one were willing to accept such difference as signifi-
cant, it would further strengthen the association between
ADPKD and posttransplant diabetes mellitus because
the control group was on a higher prednisone dose at
that time point. The prednisone dose at 6 months and the
number of acute rejection episodes (used as a surrogate
marker of higher steroid dosage for study purposes) were
not different between cohorts. The use of other immuno-
suppressive agents such as tacrolimus and cyclosporine
A has been associated with posttransplant diabetes mel-
litus [11]. However, this factor was accounted for by the
matching strategy employed in this study.
The use of diuretics (especially of the thiazide class)
and of beta blockers as antihypertensive agents has been
associated with glucose intolerance and posttransplant
diabetes mellitus [22]. In our report, the use of diuretics,
but not the use of beta blockers, was marginally associated
with the development of posttransplant diabetes mellitus.
Adjusting for the use of diuretics and beta blockers did
not weaken the association between ADPKD and post-
transplant diabetes mellitus.
Previous reports have described an association be-
tween deceased donor renal transplantation and post-
transplant diabetes mellitus [14]. We were unable to
demonstrate such an association in our study. However,
the finding of an association between delayed graft func-
tion and posttransplant diabetes mellitus was unexpected
and deserves further investigation. It is possible that other
factors associated with delayed graft function, such as
ethnicity, could be functioning as confounders in our
analyses.
The impact of body weight on the risk for development
of posttransplant diabetes mellitus has been previously
described [23]. At 1 year, the overall risk of posttransplant
diabetes mellitus was significantly greater in recipients
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with BMI greater than 30 kg/m2 at 1 year, when compared
to their nonobese counterparts. Our study showed that
obesity, either at the time of transplantation or at 1-year
post transplant, was not different between the ADPKD
and control groups, therefore an unlikely explanation for
this association. This inference was supported by the mul-
tivariable analysis results. Furthermore, in patients with
ADPKD, due to the amount of fluid contained inside the
cysts, there might have been an overestimation of BMI
because of the weight of the native kidneys and other
organs affected by the polycystic condition. Using BMI
in this group would then overestimate their “effective
weight,” which may further add to the contention that
there is an increased risk for posttransplant diabetes mel-
litus in the ADPKD patients for other reasons than body
weight.
The mechanisms implicated in this association should
be a target for future research. Due to the extremely
low incidence of pancreatic cysts described in ADPKD
patients and their unknown impact on the insulin pro-
duction and secretion, the presence of such cysts is an
unlikely explanation for the higher incidence of post-
transplant diabetes mellitus in this population. Similarly,
the significance of the presence of liver cysts in the hep-
atic pathways of glucose disposal is unknown. Our study
has not addressed such important issues due to the small
sample size and inconsistencies in reports from radiolog-
ical or ultrasonographic studies describing cysts in these
organs. One can hypothesize that ADPKD subjects may
be at increased risk for steroid-associated insulin resis-
tance. Perhaps a yet unidentified gene(s) associated with
insulin resistance could be coinherited at a greater rate
by individuals with the ADPKD gene(s). Alternatively,
as the functions of the proteins coded by the defective
polycystic genes are largely unknown, one could postu-
late that the development of glucose intolerance in the
setting of metabolic stress could be directly or indirectly
related to these defective gene products.
Kassiske et al [10] have described a lower incidence of
posttransplant diabetes mellitus in a cohort of patients
with a pre transplant diagnosis of glomerulonephritis. A
potential explanation for this observation is that patients
most likely to developed diabetes did so when initially
treated with glucocorticosteroids for their underlying dis-
ease. This phenomenon could have introduced a selection
bias in our study, as just the patients less likely to develop
diabetes would remain eligible for entering the study co-
horts. Unfortunately, data on glucocorticoid use prior to
transplantation were not available in the database. How-
ever, our additional analysis showed that the incidence of
posttransplant diabetes mellitus in recipients without the
diagnosis of glomerulonephritis (therefore less likely to
have received glucocorticoid previously) was similar to
the matched cohort. This supports the idea that selection
bias would be an unlikely explanation for our findings.
Short-term follow-up could be seen as a weakness in
our report. However, as previously reported, the vast
majority of renal recipients who went on to develop
posttransplant diabetes mellitus manifested this condi-
tion within the first year after transplantation. Since our
study cohort comprised predominantly Caucasians, sim-
ilar studies are warranted to further investigate the pres-
ence of such association in other ethnic groups.
CONCLUSION
Our study describes a significant association between
ADPKD and the development of posttransplant diabetes
mellitus within the first year following renal transplan-
tation. Development of posttransplant diabetes mellitus
was associated with a significant detrimental impact on
patient survival. The mechanism involved in such an as-
sociation merits further investigation.
NOTE ADDED IN PROOF
Since the submission of this manuscript, some publica-
tions on the topic have replaced the term “posttransplant
diabetes mellitus” with “new onset diabetes after trans-
plantation” (NODAT or NODM). The authors would
like to support this change in nomenclature. However, at
this point of the publication process such change would
be impractical.
Reprint requests to Angelo M. de Mattos, M.D., University of Alabama
at Birmingham, Division of Nephrology, 1900 University Boulevard,
THT 647, Birmingham, AL 35294–0006.
E-mail: demattos@uab.edu
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